[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100442419","hyperpolarized-129-xenon-imaging-in-adult-hematopoietic-cell-transplant-recipients-with-pulmonary-impairment-100442419",false,"NCT05041140","Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment","Inclusion Criteria:\n\n\\- Allo-HCT recipients who are at least 18 years of age and have BOS (n=10 patients), BOS 0p (n = 10 patients), or cGVHD of a non-lung organ without evidence of pulmonary impairment (n = 5 patients).\n\nHealthy Cohort - Inclusion Criteria:\n\nWe will perform only XeMRI imaging on 10 healthy adult (18 years and older) volunteers with no medical issues for technical calibration of the XeMRI technology. Members of the study team may serve as healthy volunteers if they have no prior history of lung disease. These data will not be included as part of the analysis.\n\nExclusion Criteria:\n\n1. Participants unable to follow up at MD Anderson for routine clinical care\n2. Inability or unwillingness to give informed consent\n3. Relapsed disease or life expectancy less than 6 months at time of enrollment\n4. Severe claustrophobia precluding MRI imaging\n5. Active pulmonary infection\n6. Pregnant women",true,"ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","OBSERVATIONAL","This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD).\n\nThe primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements.\n\nA secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.",[24,25,26],"Pulmonary","Pneumonia","Hematopoietic System--Cancer","RECRUITING","2026-08-07",{"date":30,"type":31},"2026-08-10","ACTUAL",{"date":33,"type":31},"2024-08-14",{"date":35,"type":20},"2027-07-20",{"name":37,"class":38},"M.D. Anderson Cancer Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":39},"100609773","universal-biospecimen-collection-protocol-for-extra-material-from-clinical-pulmonary-procedures-100609773","NCT07218939","Universal Biospecimen Collection Protocol for Extra Material From Clinical Pulmonary Procedures","Inclusion Criteria:\n\nAll patients over the age of 18, who are seen in the Cardiopulmonary Center and are undergoing pulmonary procedures\n\nExclusion Criteria:\n\nPregnant women and prisoners",{"count":47,"type":20},12000,"The goal of this study is to develop a biospecimen collection protocol for unused biospecimens from pulmonary procedures in order to facilitate research across many different areas of pulmonary medicine and mitigate the pulmonary morbidity experienced by patients with cancer.",[24],"2026-05-18",{"date":52,"type":31},"2026-05-19",{"date":54,"type":31},"2025-10-08",{"date":56,"type":20},"2032-12-01",{"name":37,"class":38},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":5},"100617598","breathlessness-diagnostics-in-a-box-biab-for-primary-care-a-multi-country-quality-improvement-project-using-a-randomized-stepped-wedge-design-100617598","NCT07320703","\"Breathlessness Diagnostics in a Box\" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge Design","BiaB","The study aims to capture the real-world heterogeneity in primary care practices and patients. Therefore, inclusion and exclusion criteria are limited.\n\nInclusion criteria\n\n* Patient must be at least 18 years old at the time of signing the informed consent.\n* Patients that present with undiagnosed dyspnea (breathlessness); or Patients who have existing diseases that could cause breathlessness, but have residual or increasing breathlessness that could be caused by other not yet detected diseases. Or HCP has doubts or requires additional tests to confirm diagnosis or to suspect new, parallel, diagnoses. For example, breathlessness in patients assessed within the framework of Cardiovascular Risk Management or for COPD monitoring\n\nExclusion criteria\n\n1. Acute worsening of previous diagnosed chronic disease where there is no suspicion of comorbidities (for example when a patient with clear COPD diagnosis has an exacerbation where typically the HCP will not perform additional tests).\n2. Inability to understand and sign the written consent form.",{"count":66,"type":20},900,"INTERVENTIONAL",[69],"NA","This prospective stepped-wedge study evaluates whether use of the Breathlessness diagnostics in a Box (BiaB) tool shortens the time to diagnosis in patients presenting with breathlessness, compared with usual care. The study is conducted in general practice settings in the Netherlands, Spain, and Portugal. Participating sites start with a usual care period and transition sequentially to the BiaB intervention period. Data are collected during routine clinical visits, from electronic medical records, and through questionnaires completed by patients and healthcare professionals.",[72,73,24,74],"Breathlessness","Cardiovascular","Mental Disease",[76,77,78,79,80,81],"breathlessness","diagnostics","cardiovascular disease","pulmonary disease","mental disease","cardiopulmonary risk","2026-01-06",{"date":84,"type":31},"2026-01-07",{"date":86,"type":31},"2024-08-05",{"date":88,"type":20},"2027-04",{"name":90,"class":91},"General Practitioners Research Institute","NETWORK"]